氨甲酰脲,CAS 登记号 16118-49-3,由济南圣和化工有限公司现货供应,可提供纯度 按批次COA提供(不公开发布) 的规格,下游主要用于医药中间体及原料药。支持样品与小批量试用,批量价格请联系我们获取,验收以批次 COA 为准。
医药中间体及原料药
每批随货提供 COA;可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号,一个工作日内回复报价。
本页已列出 氨甲酰脲 的 CAS 号:16118-49-3,可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布),包装形式为 按订单/批次确认(不公开发布),特殊规格可在询价时说明。
主要涉及医药中间体及原料药。
来信 info@591daili.com 或 WhatsApp 联系,提供产品名称、CAS 号与数量,确认价格与交期后即可安排发货,验收以批次 COA 为准。
carbetamide · CAS 16118-49-3 · C12H16N2O3. UNII A75ON2B2V7. LogP: 1.0.
| CAS Registry Number | 16118-49-3 |
|---|---|
| PubChem CID | 152031 |
| Molecular formula | C12H16N2O3 |
| IUPAC name | [(2R)-1-(ethylamino)-1-oxopropan-2-yl] N-phenylcarbamate |
| UNII (FDA) | A75ON2B2V7 |
| Molecular Weight | 236.27 |
|---|---|
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 236.11609238 |
| Monoisotopic Mass | 236.11609238 |
| Topological Polar Surface Area | 67.4 |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| LogP | 1.0 |
|---|
| Reported hazard statements | H302, H351, H411, H360 (51.5%) |
|---|
H302: Harmful if swallowed [Warning Acute toxicity, oral]
H351: Suspected of causing cancer [Warning Carcinogenicity]
CARBETAMIDE; 16118-49-3; Carbetamex; Carbethamide; Legurame PM; Carbetamid; D-N-Ethyllactamide carbanilate; D-N-Ethylacetamide carbanilate; A75ON2B2V7; (R)-1-(Ethylcarbamoyl)ethyl carbanilate; D-N-Ethyllactamide carbanilate (ester); RP-11561; (Phenylcarbamoyloxy)-2-N-ethylpropionamide; 2-Phenyl-carbamoyloxy-N-aethyl-propionamid; D-(-)-1-(Ethylcarbamoyl)ethyl phenylcarbamate; (R)-N-Ethyl-2-(((phenylamino)carbonyl)oxy)propanamide
CAS 16118-49-3; molecular formula C12H16N2O3; molecular weight — g/mol.
CARBETAMIDE, 16118-49-3, Carbetamex, Carbethamide, Legurame PM, Carbetamid.
Hazard statements reported: H302, H351, H411, H360.
LogP: 1.0.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.